Apheresis Market Expected to Secure Notable Revenue Share During 2022-2030 – Travel Adventure Cinema

0

The global apheresis market was rated at $2,413.3 million in 2021. It is expected to reach USD 4773.4 million by 2030, registering a CAGR of 8.9% from 2022 to 2030. Apheresis is a medical technology in which a person’s blood is passed through a device that separates a particular constituent and returns the rest to circulation. The market studied is currently influenced by factors such as increasing global disease burden resulting in increased demand for blood components, technological advancements in the development of new apheresis techniques and increasing reimbursement policies and funding for apheresis procedures.

Other major factors attributing to the growth of the apheresis market are an increase in the burden of chronic diseases, such as cancer, multiple sclerosis (MS) cases, rheumatoid arthritis (RA) and an increase in the budgets of health in many countries. For example, according to the study published in November 2020, entitled “Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition”, it is estimated that a total of 2.8 million people are living with MS in worldwide (35.9 per 100,000 population) and the prevalence of MS has increased in all regions of the world since 2013. Moreover, according to the same source, the combined incidence rate in 75 reporting countries was 2. 1 per 100,000 people/year, and the average age of diagnosis is 32 years. Apheresis procedures, such as therapeutic plasma exchange and immunoadsorption, can treat multiple sclerosis. The growing prevalence of MS is expected to positively drive the apheresis market.

Get a sample full PDF copy of [email protected]https://www.marketstatsville.com/request-sample/market-apheresis

covid19 Global Apheresis Market Impact

The COVID-19 outbreak, worldwide, is expected to have a positive impact on the market studied, as apheresis is a medical technique in which the blood of an individual, whether donor or patient, is passed to through an apparatus that separates a particular constituent. and returns the rest to the bloodstream. This technique is now widely used to treat COVID-19 as plasma therapy.

Due to lockdown measures, trade restrictions and high infection rate. Their work has been impacted, especially R&D activities, as clinical trials and other types of trials have been delayed for more than six months. Additionally, there has been a decline in the market capitalization of major corporations around the world, as well as a decline in industrial production and other business activities.

Global apheresis market dynamics

Drivers: Increased global burden of disease resulting from increased demand for blood components and associated safety

Apheresis has seen a high demand due to an increased number of patients suffering from various blood, kidney, metabolic and neurological diseases. Leukemia, lymphoma, myeloma, and myelodysplastic syndromes (MDS) are types of cancer that can affect bone marrow, blood cells, lymph nodes, and other parts of the lymphatic system. It has been observed that apheresis technology has been used to reduce the number of white blood cells until other drugs can control them. For example, leukemia is characterized by an abnormal increase in white blood cells making the blood thick.

Cancer is one of the most common chronic diseases in the UK. According to the GLOBOCAN 2020 report, 457,960 new cases of cancer were reported in 2020, of which 16,806 were non-Hodgkin lymphoma cancers, 14,110 kidney cancers, 11,008 leukemias and 6,377 multiple myelomas. This high prevalence of blood-related cancers is expected to significantly accelerate the growth of the apheresis market.

Constraints: High capital investment and costs associated with apheresis procedures

Apheresis procedures and devices, being relatively complex, are generally expensive to undergo. Additionally, many insurance companies claim that they may not reimburse the costs of these procedures in some cases. This results in large out-of-pocket costs for patients and restrains market growth. In the United States, the cost of apheresis therapy is high and can be around USD 2,500 per session for LDL apheresis (University of Michigan, 2017). The high cost of this procedure is a significant constraint for many patients. High costs are also common around the world when the procedure is not covered by insurance companies or subsidized by the government.

The annual costs for patients who need to undergo these procedures regularly become very high, especially for LDL apheresis. For example, according to the study cited above, conducted in 2017 by the University of Michigan in the United States, the annual cost of a weekly treatment can vary between 114,504 USD and 228,956 USD. In countries like Australia and the United States, patient costs also exceed $100,000. Thus, patients with chronic conditions may find it very difficult to cover these expenses.

Scope of apheresis

The study categorizes the apheresis market based on product, apheresis procedure, technology, and application regionally and globally..

By Product Perspective (Sales/Revenue, USD millions, 20172030)

By outlook apheresis procedure (Sales/Revenue, USD million, 20172030)

  • Leukapheresis
  • Plasmapheresis
  • Plaquettetheresis
  • Erythrocytapheresis
  • Other apheresis procedures

By Technology Insights (Sales/Revenue, USD millions, 20172030)

  • centrifugation
  • Membrane separation

By Outlook app (Sales/Revenue, USD million, 20172030)

  • Kidney disorders
  • Hematological disorders
  • Neurological disorders
  • Autoimmune disorders
  • Other Apps

Outlook by region (Sales/Revenue, USD million, 20172030)

  • North America (United States, Canada, Mexico)
  • South America (Brazil, Argentina, Colombia, Peru, Rest of Latin America)
  • Europe (Germany, Italy, France, United Kingdom, Spain, Poland, Russia, Slovenia, Slovakia, Hungary, Czech Republic, Belgium, Netherlands, Norway, Sweden, Denmark, Rest of Europe)
  • Asia Pacific (China, Japan, India, South Korea, Indonesia, Malaysia, Thailand, Vietnam, Myanmar, Cambodia, Philippines, Singapore, Australia and New Zealand, Rest of Asia Pacific)
  • The Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa, North Africa, Rest of MEA)

The disposable segment expected to account for the largest market share, by product

Global apheresis market is split into devices and disposables based on product. In 2021, the disposable products segment accounted for the largest market share of 57.5% in the global apheresis market. Disposable products include sets, drainage bags, blood bags, tubing, replacement fluids and blood thinners in the apheresis market. According to the National Institutes of Health Clinical Center May 2021 report, each year more than 30,000 units of platelets are transfused at their center to treat patients undergoing cancer treatment, organ and tissue transplants and transplants. ‘other diseases requiring platelet therapy during which the number of disposables is used, thus, one of the growth factors for the segment.

Inquire Before Buy @ https://www.marketstatsville.com/buy-now/apheresis-market?opt=2950

Apheresis procedures are used to separate plasma or blood components. Blood is drawn from the donation arm by a pump into a sterile single-use disposable kit inside the cell separation machine during a plasma donation. Thus, the rise in donations could boost the demand for disposable products and boost the growth of the segment.

Asia Pacific represents the highest CAGR over the forecast period

On the basis of region, the global apheresis market has been segmented into North America, AsiaPacific, Europe, South America, Middle East and Africa. Globally, Asia-Pacific is expected to register a CAGR of 10.4% during the forecast period. In the Asia-Pacific region, China holds the largest market share in 2021. China represents one of the leading healthcare industries in the Asia-Pacific region. China is one of the world’s leading manufacturers and consumers of plasma-derived products and serves a huge population. Blood and plasma products are considered strategic resources in China. The major factors driving the growth of the apheresis market in China are the increasing prevalence of chronic diseases associated with blood disorders and the huge population requiring diverse medical care.

In addition, Japan is a great innovative country in the medical field. During the forecast period, the growth of the Japanese apheresis market is expected to be steady due to increased awareness and desire in society to improve the healthcare industry. LDL apheresis was developed to treat refractory familial hypercholesterolemia (FH). Currently, plasma exchange, double membrane filtration and selective LDL adsorption are available in Japan. Selective LDL adsorption is the most common method.

Main market players

The apheresis market is slightly concentrated in nature with few global players operating in the market, such as Haemonetics Corporation, Asahi Kasei Medical Co., Ltd, HemaCare Corporation, Fresenius Kabi, Terumo BCT, Inc., Kaneka Corporation, Kawasumi Laboratories Inc., Cerus Corporation, B. Braun Melsungen AG and Nikkiso Co., Ltd..

Request for Full Table of Content and Figures & Charts @ https://www.marketstatsville.com/table-of-content/apheresis-market

Share.

Comments are closed.